Aligos Therapeutics (ALGS) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 25, 2026, to be held virtually for stockholders of record as of April 27, 2026.

• Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request.

Voting matters and shareholder proposals

• Election of two Class III directors, Bridget Martell and Carole Nuechterlein, to serve until the 2029 annual meeting.

• Ratification of Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026.

• Amendment to the 2020 Employee Stock Purchase Plan to remove the evergreen provision and increase reserved shares by 500,000.

• Advisory vote on executive compensation (Say-on-Pay).

• Advisory vote on the frequency of Say-on-Pay votes, with the board recommending every one year.

Board of directors and corporate governance

• Board recommends voting for all proposals and for a one-year frequency on Say-on-Pay.